The UK Approves Telix’s Illuccix for Advanced Prostate Cancer Imaging

Telix has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Illuccix®, a PET imaging agent designed to detect and locate PSMA-positive prostate cancer lesions. 

Gary Cook, MD, Professor of Molecular Imaging at Kings College London School of Biomedical Engineering & Imaging Sciences, said in a statement, “PSMA-PET supply shortages in the UK and Europe have escalated over the past 12 months as demand increases, which has led to delays for men in urgent need of a scan to direct clinical management. It is great news that Telix can now help address this unmet need and improve equity of access in the UK through their Illuccix imaging agent and network distribution model.”

Medical authorities in the UK approve Illuccix for detecting and locating PSMA-positive prostate cancer lesions through PET in adult patients. The PSMA-PET imaging technique has emerged as a groundbreaking innovation in prostate cancer care by superseding standard diagnostic techniques of bone scans along with CT scans to establish the standard of care during initial diagnosis and biochemical recurrence stages.  

PSMA-PET imaging is one of the most important developments in prostate cancer detection in recent years, and we are delighted that we can bring Illuccix to physicians and their patients across the UK. A key advantage of Illuccix is that the radioisotope (gallium-68) can be produced locally using a generator, taking just a few minutes with minimal equipment. Reliable service delivery combined with greater scheduling flexibility, including in non-metropolitan locations, will benefit patients, physicians and clinical sites in the UK,” commented Raphaël Ortiz, Chief Executive Officer, Telix International. 

Every major medical organization emphasizes how precisely PSMA-PET detects prostate cancer at its initial stages and evaluates both biochemical recurrences after treatment and persistent biochemical activity. Illuccix will be available in the UK through Xiel Limited, Telix’s exclusive distribution partner specializing in nuclear medicine and radiology.